Michael C Jundt1,2, Edwin A Takahashi1,2, William S Harmsen3, Sanjay Misra4,5. 1. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Division of Vascular and Interventional Radiology, Mayo Clinic, Rochester, USA. 3. Department of Clinical Statistics, Mayo Clinic, Rochester, MN, USA. 4. Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. misra.sanjay@mayo.edu. 5. Division of Vascular and Interventional Radiology, Mayo Clinic, Rochester, USA. misra.sanjay@mayo.edu.
Abstract
PURPOSE: To determine primary rates in small-diameter renal arteries, including complex bifurcation lesions, treated with drug-eluting stents (DES) in patients with atherosclerotic renal artery stenosis. MATERIALS AND METHODS: This is a retrospective single-institution study. A total of 37 patients with 39 stented renal arteries were included. Patient and procedural data were obtained from the electronic medical record. Survival free from restenosis was estimated using the Kaplan-Meier method with patients stratified into two groups based on renal artery diameters (≤ 3.5 mm or > 3.5 mm). Univariate Cox proportional models were used to estimate hazard ratios associated with clinical and angiographic variables. RESULTS: Average renal artery diameter at time of treatment was 3.4 mm ± 0.4 mm. The median survival free from restenosis was 992 days, with 11 out of 37 (29.7%) developing an in-stent restenosis. Renal arteries < 3.5 mm in diameter had similar patency rates as renal arteries > 3.5 mm (P = 0.33). The 1-, 2-, and 5-year patency rates were 71%, 63%, and 38%, respectively. History of stroke was the only comorbidity to portend a significantly greater rate of restenosis (hazard ratio 3.77; 95%CI, 1.05-13.6; P = 0.04). Medications did not statistically alter the risk of restenosis. CONCLUSION: Revascularization of renal arteries with DES achieved similar primary patency rates irrespective of renal artery diameter. Stent configuration was not associated with time to renal replacement therapy or all-cause mortality. LEVEL OF EVIDENCE: Level 3, Cohort Study.
PURPOSE: To determine primary rates in small-diameter renal arteries, including complex bifurcation lesions, treated with drug-eluting stents (DES) in patients with atherosclerotic renal artery stenosis. MATERIALS AND METHODS: This is a retrospective single-institution study. A total of 37 patients with 39 stented renal arteries were included. Patient and procedural data were obtained from the electronic medical record. Survival free from restenosis was estimated using the Kaplan-Meier method with patients stratified into two groups based on renal artery diameters (≤ 3.5 mm or > 3.5 mm). Univariate Cox proportional models were used to estimate hazard ratios associated with clinical and angiographic variables. RESULTS: Average renal artery diameter at time of treatment was 3.4 mm ± 0.4 mm. The median survival free from restenosis was 992 days, with 11 out of 37 (29.7%) developing an in-stent restenosis. Renal arteries < 3.5 mm in diameter had similar patency rates as renal arteries > 3.5 mm (P = 0.33). The 1-, 2-, and 5-year patency rates were 71%, 63%, and 38%, respectively. History of stroke was the only comorbidity to portend a significantly greater rate of restenosis (hazard ratio 3.77; 95%CI, 1.05-13.6; P = 0.04). Medications did not statistically alter the risk of restenosis. CONCLUSION: Revascularization of renal arteries with DES achieved similar primary patency rates irrespective of renal artery diameter. Stent configuration was not associated with time to renal replacement therapy or all-cause mortality. LEVEL OF EVIDENCE: Level 3, Cohort Study.
Authors: Marc Sapoval; Markus Zähringer; Peter Pattynama; Claudio Rabbia; Claudio Vignali; Geert Maleux; Louis Boyer; Malgorzata Szczerbo-Trojanowska; Werner Jaschke; Geir Hafsahl; Mark Downes; Jean Paul Beregi; Nic Veeger; Aly Talen Journal: J Vasc Interv Radiol Date: 2005-09 Impact factor: 3.464
Authors: Keith Wheatley; Natalie Ives; Richard Gray; Philip A Kalra; Jonathan G Moss; Colin Baigent; Susan Carr; Nicholas Chalmers; David Eadington; George Hamilton; Graham Lipkin; Anthony Nicholson; John Scoble Journal: N Engl J Med Date: 2009-11-12 Impact factor: 91.245
Authors: Alan T Hirsch; Ziv J Haskal; Norman R Hertzer; Curtis W Bakal; Mark A Creager; Jonathan L Halperin; Loren F Hiratzka; William R C Murphy; Jeffrey W Olin; Jules B Puschett; Kenneth A Rosenfield; David Sacks; James C Stanley; Lloyd M Taylor; Christopher J White; John White; Rodney A White; Elliott M Antman; Sidney C Smith; Cynthia D Adams; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Sharon A Hunt; Alice K Jacobs; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel Journal: Circulation Date: 2006-03-21 Impact factor: 29.690
Authors: Sanjay Misra; Mallik R Thatipelli; Patrick W Howe; Christopher Hunt; Verghese Mathew; Gregory W Barsness; Axel Pflueger; Stephen C Textor; Haraldur Bjarnason; Michael A McKusick Journal: J Vasc Interv Radiol Date: 2008-04-28 Impact factor: 3.464
Authors: David J Kennedy; William R Colyer; Pamela S Brewster; Mary Ankenbrandt; Mark W Burket; Attila S Nemeth; Sadik A Khuder; William J Thomas; Joseph I Shapiro; Christopher J Cooper Journal: Am J Kidney Dis Date: 2003-11 Impact factor: 8.860